Better Health for All

4D Molecular Therapeutics (4DMT) is a clinical-stage gene therapy company focused on developing transformative treatments for serious diseases with unmet medical needs, such as Fabry disease cardiomyopathy, blinding retinal vascular diseases (wet AMD, diabetic macular edema), and cystic fibrosis.

All of its product candidates are in clinical or preclinical development, with none yet approved for marketing. For Fabry disease, 4D-310 showed improvement in cardiac contractility, exercise capacity, and quality of life in all three patients with 12 months of follow-up, with transgene expression in ~50% of cardiomyocytes. The company targets patients with rare diseases and limited or no treatment options, and its trials include a broad and diverse Fabry disease patient population, addressing diseases affecting older adults, individuals with diabetes, and children/young adults. However, the company voluntarily paused enrollment in January 2023 for its 4D-310 trials after observing an aHUS dose-limiting toxicity in three patients, leading to an FDA clinical hold. The company is engaging with the FDA to lift the hold and resume enrollment with updated exclusion criteria and an immunosuppressive regimen. The company's Code of Business Conduct and Ethics emphasizes full, fair, accurate, timely, and understandable disclosure. 4DMT utilizes its proprietary Therapeutic Vector Evolution platform, which incorporates approximately one billion synthetic AAV capsid-derived sequences, for its product candidates. The company completed enrollment for its 4FRONT-1 Phase 3 clinical trial of 4D-150 in wet AMD in February 2026 and announced FDA clearance for an investigational product in July 2025.

Fair Money & Economic Opportunity

4D Molecular Therapeutics, Inc. (FDMT.US) is a clinical-stage gene therapy company, not a financial institution.

The company does not offer lending, deposit, or other financial services to consumers. Therefore, all KPIs related to fair money and economic opportunity, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility for financial products, fair lending compliance, wealth building outcomes for customers, profit reinvestment in community finance, financial literacy initiatives, debt burden ratio, geographic inclusion for banking services, and product simplicity for financial products, are not applicable to its business model.

Fair Pay & Worker Respect

85% of employees would recommend working at the company, and 88% approve of the CEO.

The overall employee rating is 4.0 out of 5 stars. The company also received a 4.5 out of 5 stars rating for Culture and Values, and a 4.3 out of 5 stars rating for Compensation and Benefits.

Honest & Fair Business

The company has a whistleblower policy and an anti-corruption compliance policy, both of which are monitored by the Audit Committee.

However, no further details are provided regarding their strength, enforcement, or effectiveness. Six out of seven board members are considered independent directors, as defined under Nasdaq rules, which equates to approximately 85.7% independent directors. The Human Capital Committee retained Pearl Meyer as an independent consultant, who reports directly to the committee and provides no other services to management, and whose independence was assessed in accordance with SEC and Nasdaq rules.

Kind to Animals

The company uses both in vivo (animal) and in vitro (cell) models for evaluation, specifically deploying its Therapeutic Vector Evolution platform with capsid libraries in non-human primates (NHPs) for competitive selection.

Preclinical data is derived from NHP and human cell models, indicating that traditional animal assays dominate the core development process. The company is subject to registration, inspections, and reporting requirements under the Animal Welfare Act (AWA), but no specific policy on animal testing reduction or alternatives is provided. The company has completed 14 unique vector selection programs, which involve animal testing, but does not provide annual animal usage numbers or reduction targets. While the company conducts in vitro evaluation in cell models, there is no evidence of formal collaboration in multi-stakeholder initiatives for animal-free testing standards. The company has no public position on animal welfare legislation or advocacy for higher standards.

No War, No Weapons

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company focused on developing AAV vectors for targeted therapies for medical conditions such as Fabry disease and Cystic Fibrosis.

The company's core business, product pipeline, and collaborations are entirely within the medical and pharmaceutical sectors. There is no evidence in the provided articles to suggest that the company derives any revenue from arms or defense contracts, develops or sells dual-use products with military applications, uses AI militarily, or has any involvement in surveillance or weapons-related activities. Therefore, several KPIs are scored as N/A, indicating no defense or arms-related activities in its core business.

Safe & Smart Tech

The company experienced one phishing attack in September 2019, but no data was accessed or compromised, meaning no data breach occurred.

The company states it has implemented security measures to protect data and IT systems and has a cybersecurity risk management program based on the NIST CSF, with quarterly reports to the Audit Committee. It also has an incident response plan. The company is subject to and mentions compliance with various privacy regulations, including HIPAA, GDPR, CCPA, CPRA, and COPPA, and its privacy notices detail user rights to access, update, or remove personal information. The company has a whistleblower hotline and website for reporting concerns, and all Accounting Complaints and related documents are retained for at least five years. The company mentions a risk of unauthorized access or use of IT systems but no incidents of unauthorized data use are documented. The company states it will provide appropriate funding for investigations, but no specific cybersecurity investment percentage is provided. The company mentions implementing security measures to mitigate network security problems and vulnerabilities, but no specific vulnerability management metrics are available. No specific data on employee security training, authentication methods, data minimization, privacy by design, security testing coverage, bug bounty programs, or encryption implementation is provided. The company mentions a Machine Learning SRA, but no details on AI ethics governance, audit practices, algorithmic transparency, or harm remediation are available. No information on privacy certifications or digital rights advocacy is provided.

Zero Waste & Sustainable Products

The provided articles do not contain any specific, concrete data points or facts related to waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability scores, waste audit frequency, zero waste certifications, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education for 4D Molecular Therapeutics, Inc.

Therefore, no KPIs can be scored against the 'Zero Waste & Sustainable Products' value.